Discovery of a Highly Selective STK16 Kinase Inhibitor

Citations Over TimeTop 18% of 2016 papers

Abstract

STK16, a serine/threonine protein kinase, is ubiquitously expressed and is conserved among all eukaryotes. STK16 has been implicated to function in a variety of cellular processes such as VEGF and cargo secretion, but the pathways through which these effects are mediated remain to be elucidated. Through screening of our focused library of kinase inhibitors, we discovered a highly selective ATP competitive inhibitor, STK16-IN-1, which exhibits potent inhibitory activity against STK16 kinase (IC50: 0.295 μM) with excellent selectivity across the kinome as assessed using the KinomeScan profiling assay (S score (1) = 0.0). In MCF-7 cells, treatment with STK16-IN-1 results in a reduction in cell number and accumulation of binucleated cells, which can be recapitulated by RNAi knockdown of STK16. Co-treatment of STK16-IN-1 with chemotherapeutics such as cisplatin, doxorubicin, colchicine, and paclitaxel results in a slight potentiation of the antiproliferative effects of the chemotherapeutics. STK16-IN-1 provides a useful tool compound for further elucidating the biological functions of STK16.

Related Papers

• → A transgenic approach for RNA interference-based genetic screening in mice(2006)57 cited
• → RNAi-mediated knockdown of the voltage gated sodium ion channel TcNav causes mortality in Tribolium castaneum(2016)48 cited
• → Systemic gene knockdown in Camponotus floridanus workers by feeding of dsRNA(2013)32 cited
• → Knockdown stands up(2002)37 cited
• → RNA Interference as a Tool for Producing Knockdown Mice(2005)1 cited